News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Ruben Mesa: Pelabresib plus Ruxolitinib for JAKi naive Myelofibrosis
Ruben Mesa/vjhemonc.com
Mar 12, 2025, 10:16

Ruben Mesa: Pelabresib plus Ruxolitinib for JAKi naive Myelofibrosis

Ruben Mesa, President and Executive Director of Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center, shared an article by Raajit K. Rampal, et al. on LinkedIn:

“Honored to have joined many wonderful colleagues in these important PhaseIII trial data for combination Pelabresib plus Ruxolitinib for JAKi naive myelofibrosis.”

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.

Authors: Raajit K. Rampal, et al.

Ruben Mesa: Pelabresib plus Ruxolitinib for JAKi naive Myelofibrosis

Atrium Health Levine Cancer Institute Atrium Health Wake Forest Baptist Comprehensive Cancer Center cancer fight against cancer Global fight against cancer myelofibrosis OncoDaily Oncology Pelabresib Raajit K. Rampal Ruben Mesa ruxolitinib
Special Coverage
Insight
Aug 25, 2025, 14:34
Philipp Ivanyi Highlights Need for Reconsideration in Cancer Treatment Landscape
Voices
Aug 25, 2025, 14:32
Douglas Flora: America Is Abandoning One of the Greatest Medical Breakthroughs
Insight
Aug 25, 2025, 14:21
Anirban Maitra Highlights New Paper on Therapeutic Targets for Pancreatic Cancer
OncoDaily Pulse
Aug 25, 2025, 14:16
Padraic O’Malley: Meet the Experts of VIRO 2025
Insight
Aug 25, 2025, 14:15
Hidden Risks: BRCA Mutations and Breast Implants - CancerWorld
Voices
Aug 25, 2025, 13:49
Mario I Fernandez: Joining LATAM Bladder Cancer Experts at the IBCG in Houston
Voices
Aug 25, 2025, 13:34
Gevorg Tamamyan: Hemostasis Today - A New Era in Hemostasis and Thrombosis Reporting
Career Updates
Aug 25, 2025, 13:16
Jouliana Sadek Joins the Kyowa Kirin North America Team as Associate Director, Medical Value Outcomes Liaison
FDA Approvals
Aug 25, 2025, 13:00
FDA Breakthrough Therapy Designation for Iza-bren: Advancing Treatment for EGFR-Mutant NSCLC
Science
Aug 25, 2025, 12:37
Stephen V Liu: Chronic Kidney Disease Risk After Cisplatin Chemotherapy
Insight
Aug 25, 2025, 12:23
Catharine Young: Why We Fund Science and Specifically mRNA Research
Voices
Aug 25, 2025, 12:17
Amalya Sargsyan: Some People Don’t Just Save Lives, They Change the Way Others Do It